Jefferies Remains a Buy on Sanofi (SNYNF)

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The company’s shares closed last Tuesday at $95.45.

According to TipRanks, Welford is a 4-star analyst with an average return of 4.0% and a 54.40% success rate. Welford covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and GlaxoSmithKline.

In addition to Jefferies, Sanofi also received a Buy from Stifel Nicolaus’s Eric Le Berrigaud in a report issued today. However, on July 3, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF).

The company has a one-year high of $112.73 and a one-year low of $86.12. Currently, Sanofi has an average volume of 17.13K.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Sanofi (SNYNF) Company Description:

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.